Works matching IS 11738804 AND DT 2024 AND VI 38 AND IP 6

Results: 10

Pulmonary Arterial Hypertension and TGF-β Superfamily Signaling: Focus on Sotatercept.

Published in:

BioDrugs, 2024, v. 38, n. 6, p. 743, doi. 10.1007/s40259-024-00680-3

By:

Stump, Benjamin;
Waxman, Aaron B.

Publication type:

Article

Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review.

Published in:

BioDrugs, 2024, v. 38, n. 6, p. 795, doi. 10.1007/s40259-024-00684-z

By:

Lee, Chae Sung;
Kulkarni, Yogesh;
Pierre, Vicki;
Maski, Manish;
Wanner, Christoph

Publication type:

Article

Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure.

Published in:

BioDrugs, 2024, v. 38, n. 6, p. 727, doi. 10.1007/s40259-024-00677-y

By:

Weber, Whitney C.;
Streblow, Daniel N.;
Coffey, Lark L.

Publication type:

Article

Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy.

Published in:

BioDrugs, 2024, v. 38, n. 6, p. 831, doi. 10.1007/s40259-024-00683-0

By:

Rivetti di Val Cervo, Pia;
Alessi, Eva;
Lastella, Marilena;
La Greca, Antonio;
Trotta, Francesco

Publication type:

Article

Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis.

Published in:

BioDrugs, 2024, v. 38, n. 6, p. 821, doi. 10.1007/s40259-024-00685-y

By:

Cevikbas, Ferda;
Ward, Alison;
Veverka, Karen A.

Publication type:

Article

Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects.

Published in:

BioDrugs, 2024, v. 38, n. 6, p. 855, doi. 10.1007/s40259-024-00679-w

By:

Wang, Wei;
Zhang, Shengnan;
Dou, Changlin;
Hu, Baihui;
Song, Hongtao;
Qi, Fan;
Zhao, Yanyan;
Li, Xiaojing;
Zhou, Ming;
Xie, Jinlian;
Deng, Kunhong;
Wu, Qian;
Ye, Ling;
Cui, Chang;
Liu, Li;
Huang, Jie;
Yang, Guoping

Publication type:

Article

Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?

Published in:

BioDrugs, 2024, v. 38, n. 6, p. 845, doi. 10.1007/s40259-024-00678-x

By:

Lenders, Malte;
Menke, Elise Raphaela;
Brand, Eva

Publication type:

Article

Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins.

Published in:

BioDrugs, 2024, v. 38, n. 6, p. 769, doi. 10.1007/s40259-024-00682-1

By:

Stephens, Amberley D.;
Wilkinson, Trevor

Publication type:

Article

Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study.

Published in:

BioDrugs, 2024, v. 38, n. 6, p. 867, doi. 10.1007/s40259-024-00681-2

By:

Bouguen, Guillaume;
Gossec, Laure;
Abitbol, Vered;
Senbel, Eric;
Bonnaud, Guillaume;
Roblin, Xavier;
Bouhnik, Yoram;
Nancey, Stéphane;
Mathieu, Nicolas;
Filippi, Jérôme;
Vuitton, Lucine;
Nahon, Stéphane;
Dellal, Azeddine;
Denis, Alice;
Foulley, Lucile;
Habauzit, Caroline;
Benkhalifa, Salim;
Marotte, Hubert

Publication type:

Article

Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab.

Published in:

BioDrugs, 2024, v. 38, n. 6, p. 755, doi. 10.1007/s40259-024-00671-4

By:

Selmaj, Krzysztof;
Roth, Karsten;
Höfler, Josef;
Vitzithum, Klaus;
Derlacz, Rafał;
von Richter, Oliver;
Hornuss, Cyrill;
Poetzl, Johann;
Singer, Barry;
Jacobs, Laura

Publication type:

Article